Shamburg News · 8-K filed Nov 12, 2026, 4:10 PM EST

Relmada Therapeutics Reports Preliminary Third Quarter 2026 Results and Business Update

RLMD · RELMADA THERAPEUTICS, INC.

  • Earnings
  • Other event
  • Reg FD disclosure
  • Materiality: high

On November 12, 2026, Relmada Therapeutics furnished a press release reporting preliminary, unaudited results for the third fiscal quarter ended September 30, 2026, with a net loss of $13.9 million, or $0.12 per basic and diluted share, compared with a net loss of $10.1 million, or $0.30 per share, a year earlier. The company also reported cash, cash equivalents and short-term investments of $202.1 million as of September 30, 2026, expected to fund operations through 2029, and reiterated its plan to submit the NDV-01 and sepranolone IND applications by year-end 2026. The company also updated its corporate presentation under Item 7.01, furnished as Exhibit 99.2.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, accession 0001213900-26-118933.

Written from the filing by Shamburg Markets. Figures are as reported by the company.